Introduction {#s1}
============

Quiescence is a non-proliferative cellular state found in many cell types in the body. While non-proliferative, these cells retain the ability to re-enter the cell cycle in response to appropriate cell-intrinsic and extrinsic signals ([@bib38]; [@bib54]; [@bib67]). Quiescence protects long-lived cells, such as adult stem cells against the accumulation of genomic aberrations and stress. Maintaining a pool of quiescent cells is critical for tissue repair, wound healing, and regeneration ([@bib7]). This is particularly important for epithelia which are rapidly and continuously renewed throughout life. The intestinal epithelial cells, for example, are renewed every 4 to 5 days ([@bib56]). By synchronizing cultured mammalian cells in G0 via serum starvation followed by serum re-stimulation, [@bib66] showed that the Rb proteins (pRb, p107, and p130) and their interactions with E2F proteins are critical in regulating the proliferation-quiescence decision ([@bib66]). Acting downstream, a bifurcation mechanism controlled by CDK2 activity and p21 regulating the proliferation-quiescence decision has also been demonstrated in cultured mammalian cells ([@bib53]). While important insights have been learnt from in vitro studies, how the quiescent cell pools are established during development and maintained in vivo is not well understood. The exceptionally high turnover rate implies that cell-type-specific mechanism(s) must exist.

The transient receptor potential cation channel subfamily V member 6 (TRPV6) is expressed in mammalian intestinal epithelial cells ([@bib19]). TRPV6 is a conserved calcium channel that constitutes the first and rate-limiting step in the transcellular Ca^2+^ transport pathway ([@bib19]; [@bib45]; [@bib46]; [@bib62]). In zebrafish, *trpv6* is specifically expressed in a population of epithelial cells known as ionocytes or NaR cells ([@bib12]; [@bib44]). NaR cells take up Ca^2+^ from the surrounding habitats into the body to maintain body Ca^2+^ homeostasis ([@bib33]; [@bib65]). NaR cells are polarized cells that functionally and molecularly similar to human intestinal epithelial cells. While located in the gill filaments and the intestine in the adult stages, these cells are distributed in the yolk sac skin during the embryonic and larval stages, making these easily accessible for experimental observation and perturbations ([@bib12]; [@bib44]). When zebrafish are grown in homeostatic normal \[Ca^2+^\] conditions, NaR cells are maintained in a quiescent state and the Akt-Tor activity is regulated at low levels. Low \[Ca^2+^\] stress increases Akt-Tor activity in these cells and promotes their re-entry into the cell cycle ([@bib12]; [@bib34]). This is similar to the proposed role of mTOR signaling in adult stem cells ([@bib25]; [@bib40]), suggesting an evolutionarily conserved mechanism(s) at work. More recent studies suggest that insulin-like growth factor binding protein 5a (Igfbp5a), a secreted protein that binds IGF with high-affinity, plays a critical role in activating Akt-Tor signaling in these cells via the IGF1 receptor under calcium-deficient states ([@bib35]). The mechanism controlling the quiescent state under normal \[Ca^2+^\] condition is currently unknown. In a previous study, we found that zebrafish *mus* mutant larvae, a loss-of-function Trpv6 mutant fish line obtained from an ENU mutagenesis screen ([@bib57]), had many proliferating NaR cells and elevated Akt-Tor signaling, suggesting Trpv6 may play a negative role in regulating NaR cell proliferation ([@bib12]). How does Trpv6 act to inhibit Akt-Tor signaling and whether it involves in cell quiescence regulation are unknown. Because TRPV6/Trpv6 is the primary Ca^2+^ channel responsible for epithelial Ca^2+^ uptake and since Ca^2+^ is a major second messenger involved in cell proliferation and differentiation in many cell types ([@bib11]; [@bib19]), we hypothesized that Trpv6 regulates the quiescent state by conducting Ca^2+^ influx into epithelial cells and suppressing IGF1-receptor-mediated signaling. The objective of this study was to test this hypothesis and to elucidate the underlying mechanisms of Trpv6 action.

Results {#s2}
=======

Trpv6 is crucial for epithelial Ca^2+^ uptake in zebrafish {#s2-1}
----------------------------------------------------------

Three *trpv6* mutant fish lines were generated using CRISPR/Cas9 ([Figure 1A](#fig1){ref-type="fig"}). All three Trpv6 mutant proteins lack the six transmembrane domains and the critical ion pore region and are predicted to be null mutations ([Figure 1B](#fig1){ref-type="fig"}). The *trpv6Δ7* and *trpv6Δ8* lines were made in the *Tg(igfbp5a:GFP)* fish background. *Tg(igfbp5a:GFP)* is a transgenic fish line expressing EGFP in the *trpv6*-expressing NaR cells ([@bib34]), allowing real-time analysis of NaR cell proliferation. The *trpv*6*Δ8--2* line was in a non-transgenic fish background and used in Ca^2+^ imaging analysis described later. The gross morphology and body size of the mutant fish were similar to their siblings ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). All mutant fish died within 2 weeks ([Figure 1C and D](#fig1){ref-type="fig"}). Alizarin red staining indicated a marked reduction in the calcified bone mass in the *trpv6^-/-^* mutant fish ([Figure 1E](#fig1){ref-type="fig"}), indicating body calcium deficiency. Fura-2 Ca^2+^ imaging experiments in HEK293 cells transfected with zebrafish Trpv6 and human TRPV6 were performed. The Trpv6-mediated \[Ca^2+^\]~i~ change was similar to that of TRPV6 ([Figure 1F](#fig1){ref-type="fig"}). D542 in mammalian TRPV6 occupies a critical position in the ion pore region and mutation of this residue abolishes its Ca^2+^ permeability ([@bib39]; [@bib50]). This residue is conserved in zebrafish Trpv6 at position 539 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We generated and tested Trpv6D539A mutant. The \[Ca^2+^\]~i~ levels in Trpv6D539A mutant transfected cells were low and did not respond to changes in extracellular \[Ca^2+^\] ([Figure 1F](#fig1){ref-type="fig"}). The maximal Ca^2+^ influx rate was reduced to a negligible level in Trpv6D539A transfected cells ([Figure 1G](#fig1){ref-type="fig"}). Whole-cell patch clamp experiments confirmed that the Trpv6 mediated Ca^2+^ current and this activity was abolished in the Trpv6D539A mutant ([Figure 1H](#fig1){ref-type="fig"}). These findings support the notion that Trpv6 plays an indispensable role in epithelial Ca^2+^ uptake and maintaining body Ca^2+^ balance and provided critical reagents for subsequent experiments.

![Genetic deletion of the conserved epithelial calcium channel Trpv6 results in calcium deficiency and premature death.\
(**A**) Schematic diagram showing *trpv6* gene (WT) and various mutant sequences. Filled boxes indicate *trpv6* ORF and open boxes indicate UTRs. Introns are shown as lines. The gRNA targeting site is indicated in blue color and PAM motif is underlined. Deleted and inserted nucleotides are indicated by dash lines and red letters, respectively. (**B**) Schematic diagram of Trpv6 (WT) and its mutants. Putative functional domains are indicated. The gray box indicates altered sequence caused by frame shifts. (**C--D**) Survival curves of *trpv6Δ8^-/-^; Tg(igfbp5a:GFP)* (**C**) and *trpv6Δ7^-/-^; Tg (igfbp5a:GFP)* fish (**D**) and siblings. The numbers of total fish are indicated. (**E**) Representative images of Alizarin red stained wild-type and *trpv6Δ8^-/-^; Tg(igfbp5a:GFP)* fish at 7 days post fertilization (dpf). (**F**) Fura-2 Ca^2+^ imaging analysis of HEK293 cells transfected with the indicated plasmids. n \> 50 cells from three independent experiments. (**G**) The maximal influx rate. n = 3 independent experiments. (**H**) Currents evoked by a RAMP voltage from −120 mV to +120 mV in HEK293 cells transfected with the indicated plasmids. In this and all subsequent figures, unless specified otherwise data shown are Mean ± SEM. Different letters indicate significant difference at p\<0.05, one-way ANOVA followed by Tukey's multiple comparison test.\
Figure 1---source data 1.Excel spreadsheet containing quantitative data for [Figure 1](#fig1){ref-type="fig"}.](elife-48003-fig1){#fig1}

Trpv6 regulates the quiescence-proliferation decision in epithelial cells {#s2-2}
-------------------------------------------------------------------------

To determine the possible role of Trpv6 in NaR cells, double-blind tests were performed ([Figure 2A](#fig2){ref-type="fig"}). In agreement with previous studies ([@bib12]; [@bib34]), NaR cells in the wild-type and heterozygous siblings were distributed in the yolk sac region as single cells in a salt-and-pepper pattern ([Figure 2B](#fig2){ref-type="fig"}). NaR cells in the *trpv6Δ8* mutant larvae were often observed in clusters of newly divided cells ([Figure 2B](#fig2){ref-type="fig"}). These proliferating NaR cells had enlarged apical opening ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The NaR cell proliferation rate was significantly elevated in the mutant fish in all stages examined ([Figure 2C](#fig2){ref-type="fig"}). At five dpf, the *trpv6Δ8* mutant fish had 3-time more NaR cells ([Figure 2C](#fig2){ref-type="fig"}). Essentially same data were obtained with the *trpv6Δ7* fish ([Figure 2D](#fig2){ref-type="fig"}). GdCl~3~, a Trpv6 inhibitor, was used to further test the role of Trpv6. GdCl~3~ treatment increased NaR cell proliferation in the wild-type and heterozygous fish, while it did not further increase NaR cell proliferation in the mutant fish ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Ruthenium red, another Trpv6 inhibitor, had similar effects ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Next, Trpv6 and Trpv6D539A were randomly expressed in NaR cells in *trpv6Δ8^-/^*^-^; *Tg(igfbp5a:GFP)* fish using a Tol2 transposon BAC-mediated genetic mosaic assay ([@bib35]). Reintroduction of Trpv6 reversed the quiescence to proliferation transition ([Figure 2F](#fig2){ref-type="fig"}) and reduced the apical opening size to the control levels ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Trpv6D539A, however, had no such effect ([Figure 2F](#fig2){ref-type="fig"}). These data showed that Trpv6 functions as a major barrier in the quiescence to proliferation transition and this action requires its Ca^2+^ permeability.

![Trpv6 regulates epithelial cell quiescence-proliferation decision.\
(**A**) Diagram of the experimental design. (**B**) Representative images. In this and all subsequent larval images, lateral views of the yolk-sac region are shown with dorsal up and anterior to the left. (**C--D**) Mean NaR cell number/fish of the indicated genotypes. n = 6--9. (**E**) Progenies of *trpv6 Δ8^+/-^; Tg (igfbp5a:GFP)* intercross were raised to 3 dpf and treated with 100 µM GdCl~3~ from 3 to 5 dpf. NaR cells in each fish were quantified following individual genotyping. n = 13--22. (**F**) Progenies of *trpv6Δ8^+/-^;Tg(igfbp5a:GFP)* intercross were injected with the indicated BAC-mCherry DNA at one-cell stage. At 5 dpf, the Trpv6-expressing NaR cells in each fish were scored following a published scoring system ([@bib35]). Representative images are shown in the left and quantified results in the right panel. \*\*\*\*, p\<0.0001 by Chi-Square test, fish n = 12--38.\
Figure 2---source data 1.Excel spreadsheet containing quantitative data for [Figure 2](#fig2){ref-type="fig"}.](elife-48003-fig2){#fig2}

Trpv6 controls the quiescence-proliferation decision via regulating IGF signaling {#s2-3}
---------------------------------------------------------------------------------

Previous studies showed that pre-exiting NaR cells in wild-type fish re-enter the cell cycle in response to low \[Ca^2+^\] treatment ([@bib12]; [@bib34]). To determine whether this effect is related to Trpv6, 3 dpf *trpv6Δ7^-/-^;Tg(igfbp5a:GFP)* larvae and siblings were subjected to low \[Ca^2+^\] challenge test. Low \[Ca^2+^\] treatment resulted in a three-fold increase in proliferating NaR cells in the wild-type and heterozygous fish ([Figure 3A](#fig3){ref-type="fig"}). This value was comparable to that of *trpv6Δ7^-/-^* larvae kept in normal \[Ca^2+^\] media ([Figure 3A](#fig3){ref-type="fig"}). Low \[Ca^2+^\] treatment did not further increase NaR cell number in the mutant larvae ([Figure 3A](#fig3){ref-type="fig"}). Low \[Ca^2+^\] treatment significantly increased *trpv6* mRNA level in wild-type fish and heterozygous fish, an adaptive response in Ca^2+^ homeostasis reported previously ([@bib34]). This increase, however, was abolished in *trpv6*^-/-^ mutant ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), likely due to non-sense mRNA decay of mutant *trpv6* mRNA.

![Trpv6 prevents the quiescence to proliferation transition via regulating IGF1 receptor-mediated IGF signaling.\
(**A**) Progenies of *trpv6*Δ7*^+/-^; Tg(igfbp5a:GFP)* intercrosses were grown in embryo solutions with the indicated Ca^2+^ concentration from 3 dpf to 5 dpf. NaR cells in each fish were quantified followed by individual genotyping. n = 5--17 fish. (**B--C**) Embryos of the indicated genotypes were raised to 3 dpf and treated with 0.3 µM BMS-754807 or DMSO. At 4 dpf, the treated fish were subjected to immunostaining using an anti-phospho-Akt antibody (**B**) or an anti-phospho-S6 antibody (**C**). Representative images are shown in ([Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}). n = 5--41. (**D**) Progenies of a *trpv6Δ8^+/-^; Tg (igfbp5a:GFP)* intercross were injected with the indicated BAC-mCherry DNA at one-cell stage. At 4 dpf, the larvae were subjected to phospho-Akt and mCherry double staining. (**E**) Embryos of the indicated genotypes were raised to 3 dpf and treated with 30 µM U0126 or DMSO. At 4 dpf, the treated fish were subjected to immunostaining using an anti-phospho-Erk antibody. pErk signals were scaled as shown in [@bib12]. n = 4--24. (**F--I**) Progenies of *trpv6*Δ8*^+/-^; Tg(igfbp5a:GFP)* or *trpv6*Δ7*^+/-^; Tg(igfbp5a:GFP)* intercrosses were raised to 3 dpf and treated with BMS-754807 (0. 3 µM), Wortmannin (0. 06 µM), Rapamycin (1 µM), U0126 (10 µM) or DMSO from 3 to 5 dpf. NaR cells in each fish were quantified followed by individual genotyping, n = 6--22.\
Figure 3---source data 1.Excel spreadsheet containing quantitative data for [Figure 3](#fig3){ref-type="fig"}.](elife-48003-fig3){#fig3}

Low \[Ca^2+^\] stress induces NaR cell proliferation and this has been attributed to the activation of IGF1 receptor-mediated PI3 kinase-Akt-Tor signaling ([@bib12]; [@bib34]; [@bib35]). Gene expression analysis results showed that the *igfr1a* and *igfr1b* mRNA levels were comparable between *trpv6Δ7^-/-^* larvae and siblings ([Figure 3---figure supplement 1B--1C](#fig3s1){ref-type="fig"}). Immunostaining results showed significant increases in the number of phosphorylated Akt-positive NaR cells in *trpv6Δ7^-/-^* and *trpv6Δ8^-/-^* larvae kept in the normal \[Ca^2+^\] embryo medium ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The levels of phospho-Akt in the siblings were minimal. Blocking Trpv6 channel activity using GdCl~3~ and Ruthenium red increased phospho-Akt levels in the wild-type fish ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Re-expression of Trpv6 in mutant fish inhibited Akt phosphorylation in NaR cells ([Figure 3D](#fig3){ref-type="fig"}), indicating that Trp6 is both required and sufficient in suppressing Akt signaling. Tor signaling activity was also significantly elevated in the *trpv6Δ7^-/-^* and *trpv6Δ8^-/-^* mutant larvae ([Figure 3C](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Mitogen-activated kinase (MAPK) pathway is another major signaling pathway downstream of the IGF1 receptor ([@bib15]). Immunostaining results of pErk signaling activity was significantly increased in *trpv6*^-/-^ mutant larvae ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). These data show that loss of Trpv6 expression or activity results in elevated IGF signaling in NaR cells.

If Trvp6 regulates the quiescence-proliferation decision by suppressing the IGF1 receptor-mediated signaling, then a blockade of IGF1 receptor and key downstream signaling molecules should inhibit the quiescent to proliferation transition. Indeed, treatment of *trpv6*^-/-^ mutant fish with BMS-754807, an IGF1 receptor inhibitor, abolished the quiescence to proliferation transition in mutant larvae ([Figure 3F](#fig3){ref-type="fig"}). However, IGF1 receptor inhibition did not show any significant effect on NaR cell proliferation in wild-type and heterozygous siblings ([Figure 3F](#fig3){ref-type="fig"}). Treatment of *trpv6*^-/-^ mutant fish with PI3 kinase inhibitor Wortmannin, Tor inhibitor Rapamycin, and Mek inhibitor U0126 had similar effects ([Figure 3G--3I](#fig3){ref-type="fig"}).

Trpv6 constitutively conducts Ca^2+^ into epithelial cells and regulates the \[Ca^2+^\]~i~ levels in vivo {#s2-4}
---------------------------------------------------------------------------------------------------------

To investigate Trvp6-mediated Ca^2+^ influx into NaR cells in vivo, we generated the *Tg(igfbp5a:GCaMP7a)* fish, a stable reporter fish line expressing GCaMP7a in NaR cells ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). After validating the effectiveness of GCaMP7a in reporting intracellular Ca^2+^ levels (\[Ca^2+^\]~i~) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), *trpv*6*Δ8--2*^+/-^; *Tg(igfbp5a:GCaMP7a)^+/-^* fish were crossed with *trpv*6*Δ8--2*^+/-^ fish and their offspring were screened at three dpf and subsequently genotyped individually. While GCaMP7a-positive cells were observed in \~50% of the siblings as expected, none of the *trpv*6*Δ8--2^-/-^* mutant larvae had any GCaMP7a-positive cells ([Figure 4A](#fig4){ref-type="fig"}). Addition of the Ca^2+^ ionophore ionomycin restored GCaMP7a signal in the mutant fish to a level comparable to their siblings ([Figure 4B and C](#fig4){ref-type="fig"}), thus ruling out the possibility that GCaMP7a expression is altered in the mutant fish. Next, Trpv6 was randomly expressed in NaR cells in the *trpv6 Δ8--2^-/^*^-^; *Tg(igfbp5a:GCaMP7a)* fish using the genetic mosaic assay. Reinduction of Trpv6 significantly increased GCaMP7a signal levels ([Figure 4D](#fig4){ref-type="fig"}). Ionomycin treatment did not result in further increase ([Figure 4D](#fig4){ref-type="fig"}). These genetic and in vivo imaging data argue strongly that Trpv6 is not only critical in conducting Ca^2+^ into NaR cells, but also in maintaining the high \[Ca^2+^\]~i~ levels in these cells. We next used Trpv6 inhibitors to block Trpv6 activity in *Tg(igfbp5a:GCaMP7a)* fish. Within 8 min after the GdCl~3~ treatment, the \[Ca^2+^\]~i~ levels became significantly lower and the reduction became more pronounced in 12 and 16 min ([Figure 4E and G](#fig4){ref-type="fig"}; [Video 1](#video1){ref-type="video"}). When GdCl~3~ was washed out, the \[Ca^2+^\]~i~ levels gradually increased and returned to normal levels after 12 min ([Figure 4F and G](#fig4){ref-type="fig"}; [Video 2](#video2){ref-type="video"}). Similar results were obtained with Ruthenium red ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Addition of the IGF1 receptor inhibitor BMS-754807 did not change the \[Ca^2+^\]~i~ levels in NaR cells ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Therefore, Trpv6 constitutively conducts Ca^2+^ into epithelial cells and continuously maintains high \[Ca^2+^\]~i~ levels in vivo.

![Trpv6 is constitutively open and mediates Ca^2+^ influx and maintain high \[Ca^2+^\]~i~ in epithelial cells in vivo.\
(**A**) *trpv6Δ8--2^+/-^;Tg (igfbp5a:GCaMP7a)^+/-^* was crossed with *trpv6Δ8--2^+/-.^* The progenies were imaged at three dpf followed by individual genotyping. Percentage of GCaMP7a-positive fish is shown. \*, p\<0.05 by Chi-Square test, n = 21. (**B--C**) Fish described in (**A**) were imaged before and after the addition of 7.5 µM Ionomycin + 10 mM CaCl~2~. Representative images are shown in (**B**) and the quantified results are shown in (**C**). n = 5--7. (**D**) Progenies from a *trpv6Δ8--2^+/-^;Tg (igfbp5a:GCaMP7a)^+/-^* and *trpv6Δ8--2^+/-^* intercross were injected with *BAC (igfbp5a:Trpv6-mCherry)* DNA at 1 cell stage. They were raised to three dpf. GCaMP7a signal intensity in Trpv6-mCherry-expressing cells and non-expressing NaR cells were quantified before and after the addition of 7.5 µM Ionomycin+10 mM CaCl~2~. n = 4. (**E--G**) Time-lapse images of 3 dpf *Tg (igfbp5a:GCaMP7a)* larvae after the addition of 100 µM GdCl~3~ (**E**) or following drug removal (**F**). Changes in GCaMP7a and mCherry signal intensity ratio were quantified and shown in (**G**). n = 5. \* and \*\*\*\* indicate p\<0.05 and\<0.0001 by Two-way ANOVA followed by Dunnett\'s multiple comparison test. (**H**) Wild-type larvae were treated with BAPTA-AM (100 µM) from 3 dpf to 5 dpf. NaR cells were labeled by in situ hybridization using a *trpv6* riboprobe and quantified. (**I**) Larvae described in (**H**) were stained for phosphor-Akt after 24 hr treatment. Mean ± SEM. \*\*\*\*, p\<0.0001, unpaired t-test. n = 15--19.\
Figure 4---source data 1.Excel spreadsheet containing quantitative data for [Figure 4](#fig4){ref-type="fig"}.](elife-48003-fig4){#fig4}

###### Normal Ca^2+^ + GdCl~3.~

###### Back to Normal Ca^2+^.

Trpv6 inhibits IGF signaling and epithelial cell proliferation by regulating \[Ca^2+^\]~i~ and PP2A is a downstream effector {#s2-5}
----------------------------------------------------------------------------------------------------------------------------

The observation that \[Ca^2+^\]~i~ in NaR cells are continuously maintained at high levels was surprising and intriguing. To determine whether the observed high \[Ca^2+^\]~i~ levels have any functional significance, *Tg(igfbp5a:GFP*) larvae were treated with the intracellular Ca^2+^ chelator BAPTA-AM. BAPTA-AM treatment resulted in a significant increase in NaR cell proliferation ([Figure 4H](#fig4){ref-type="fig"}) and in phospho-Akt signaling levels ([Figure 4I](#fig4){ref-type="fig"}). These data indicate that the high \[Ca^2+^\]~i~ levels are critical in maintaining the quiescent state. To identify the downstream effector(s) of \[Ca^2+^\]~i~, a collection of small molecule inhibitors with known protein targets were screened using *Tg(igfbp5a:GFP*) larvae. Okadaic acid and Calyculin A, two inhibitors of the conserved protein phosphatase 2A (PP2A), were among the strongest hits. Treatment of *Tg(igfbp5a:GFP*) larvae with either drug significantly increased NaR cell proliferation ([Figure 5A and B](#fig5){ref-type="fig"}). This effect is specific because the drug treatment had no such effect in PP2A-deficient zebrafish ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Importantly, the Okadaic acid and Calyculin A treatment-induced NaR cell proliferation was abolished by the IGF1 receptor inhibitor BMS-754807, PI3K inhibitor Wortmannin, Tor inhibitor Rapamycin, and Mek inhibitor U0126 ([Figure 5A--5C](#fig5){ref-type="fig"}). Okadaic acid or Calyculin A treatment also resulted in significant increases in the phosphorylated-Akt levels in an IGF1 receptor-dependent manner ([Figure 5D](#fig5){ref-type="fig"}). However, Okadaic acid or Calyculin A treatment did not change the \[Ca^2+^\]~i~ levels ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), indicating that PP2A acts downstream of the \[Ca^2+^\]~i.~

![PP2A is a downstream effector of Trpv6.\
(**A--B**) *Tg(igfbp5a:GFP)* embryos were treated with 1 µM Okadaic acid (OA) or 0.1 µM Calyculin A in the presence or absence of 0.3 µM BMS-754807 from 3 dpf. NaR cells were quantified at 4 and 5 dpf. Data shown are n = 10--38. (**C**) *Tg(igfbp5a:GFP)* embryos were treated with 1 µM Okadaic acid (OA) in the presence or absence of Wortmannin (0. 06 µM), Rapamycin (1 µM), U0126 (10 µM) or DMSO from 3 to 5 dpf. NaR cells were quantified at 4 and 5 dpf. Data shown are n = 16--19. (**D**) Wild-type larvae were treated with 1 µM Okadaic acid or 0.1 µM Calyculin A in the presence or absence of 0.3 µM BMS-754807 from 3 dpf to 4 dpf. They were analyzed by immunostaining for phospho-Akt. n = 9--16. (**E**) *Tg(igfbp5a:GFP)* embryos were injected with gRNAs targeting three *ppp2c* genes and Cas9 protein at one-cell stage. They were raised to five dpf. NaR cell division was quantified following a published scoring system ([@bib35]). n = 24--28. \*\*\*\*, p\<0.0001 by Chi-Square test. (**F**) The embryos treated as in (**E**) were raised to 4 dpf and analyzed by immunostaining for phospho-Akt signal. n = 20--21. \*, p\<0.05, unpaired t-test.\
Figure 5---source data 1.Excel spreadsheet containing quantitative data for [Figure 5](#fig5){ref-type="fig"}.](elife-48003-fig5){#fig5}

PP2A are a family of conserved protein phosphatases that dephosphorylate Akt and many other proteins ([@bib47]; [@bib51]). PP2A holoenzymes are heterotrimers. The core enzyme is made by a catalytic C subunit (Cα and Cβ isoform), a scaffold A subunit (Aα and Aβ), and many regulatory B subunits ([@bib59]). The combination of these subunits results in a very large number of different holoenzyme complexes. Our database search suggests that the zebrafish genome contains 3 C subunit genes (*ppp2*ca, cb, and cc). We used CRISPR/Cas9 to transiently knockdown the *ppp2c* genes because stable knockout is likely embryonic lethal. The effectiveness of the targeting guide RNAs was validated ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Transient knockdown of *ppp2cs* resulted in significant increases in the number of proliferating NaR cells ([Figure 5E](#fig5){ref-type="fig"}) and in phospho-Akt levels ([Figure 5F](#fig5){ref-type="fig"}), suggesting that PP2A mediates the action of Trpv6-mediated Ca^2+^ influx in zebrafish epithelia.

To determine whether this signaling mechanism is functional in human cells, TRPV6 knockdown experiments were performed in human LoVo colon carcinoma cells using validated siRNA ([@bib29]). These cells were synchronized by serum starvation followed by serum re-stimulation. Knockdown of TRPV6 resulted in a significant increase in LoVo cell proliferation ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Treatment of LoVo cells with Ruthenium red, GdCl~3~, BAPTA-AM, and Okadaic acid all significantly increased cell proliferation ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). MTT assay results showed little changes in cell viability in GdCl~3~, BAPTA-AM, and Okadaic-acid-treated cells. Ruthenium red treatment resulted in a modest but statistically significant decrease in cell viability ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Finally, LoVo cells were transfected with PP2A-Cα^L199P^ and PP2A-Cα^H118N^, two dominant-negative forms of catalytic subunit Cα of PP2A ([@bib23]). Expression of PP2A-Cα^L199P^ and PP2A-Cα^H118N^ both significantly increased LoVo cell proliferation ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}).

![Knockdown and inhibition of TRPV6 and PP2A increases human colon carcinoma cell proliferation.\
(**A**) LoVo cells transfected with scrambled siRNA or TRPV6 targeting siRNA were synchronized by serum starvation followed by serum re-stimulation. Cells were analyzed by flow cytometry analysis after propidium iodide staining. Percentage of S-phase cells are calculated and shown. Mean ± SEM, n = 3. \*\*, p\<0.01 by unpaired t-test. (**B**) LoVo cells were synchronized by serum starvation. They were re-stimulated with 2% FBS medium containing Ruthenium Red (RR, 100 µM), GdCl~3~ (100 µM), BAPTA-AM (100 µM), Okadaic acid (OA, 20 nM) or DMSO for 48 hr and analyzed by flow cytometry analysis after propidium iodide staining. Percentage of S-phase cells are shown. Mean ± SEM, n = 3. (**C**) LoVo cells transfected with the indicated DN-PP2A constructs were synchronized by serum starvation followed by serum re-stimulation. Cells were analyzed by flow cytometry analysis after propidium iodide staining. Percentage of S-phase cells are calculated and shown. Mean ± SEM, n = 3. \*\*\*\*, \*\*\*, \*\* indicate P\<0.0001, P\<0.001, P\<0.01 by one-way ANOVA followed by Tukey's multiple comparison test in (**B**) and (**C**). (**D**) Schematic diagram of the proposed model. See text for details.\
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Discussion {#s3}
==========

In this study, we uncover a previously unrecognized role of Trpv6 and delineates a Trpv6-mediated and evolutionarily conserved Ca^2+^ signaling pathway controlling cell quiescence ([Figure 6D](#fig6){ref-type="fig"}). We showed that genetic deletion of Trpv6 not only impaired Ca^2+^ uptake and reduced body Ca^2+^ content, but also promoted epithelial cells to exit quiescence and proliferate. Likewise, pharmacological inhibition of Trpv6 increased epithelial cell quiescence-proliferation transition. While low \[Ca^2+^\] treatment increased epithelial cell proliferation in the siblings, it had no such effect in *trpv6*^-/-^ larvae, supporting the notion that Trpv6 functions as a major regulator of the quiescent state. Our genetic mosaic analysis results showed that the quiescent state is regulated by Trpv6 in a cell autonomous manner. Reintroduction of Trpv6 in the *trpv6*^-/-^ mutant fish was sufficient to restore the \[Ca^2+^\]~i~ levels, suppress IGF signaling, and reverse the cells back to the quiescent state. The Trpv6D539A mutant had no such activity, suggesting that this action of Trpv6 requires its Ca^2+^ conductance activity.

The impaired Ca^2+^ uptake, reduced body Ca^2+^ content, and premature death observed in *trpv6Δ7* and *trpv6Δ8* mutant fish are in good agreement with a previous study by [@bib57] using the *mus* mutant fish, but differ considerable from findings made in the mouse model. Bianco et al. reported that *Trpv6* knockout mice were viable, but had reduced intestinal Ca^2+^ uptake, increased urinary Ca^2+^ excretion, decreased bone mineral density, and decreased growth and fertility ([@bib2]). Another *Trpv6*^-/-^ mutant mouse line reported by Chen et al., however, had normal blood Ca^2+^ concentration and normal bone formation, but with an increased number of osteoclasts ([@bib5]). A third *Trpv6^-/-^* mutant mouse model showed reduced fertility in male only ([@bib60]). The reason(s) of these discrepancies among these mouse studies is not fully understood, but factors such as dietary Ca^2+^ contents may have been critical ([@bib55]). Zebrafish embryos continuously lose Ca^2+^ and other ions into the surrounding hypo-osmotic environments and must constantly take up Ca^2+^ from the habitat to survive ([@bib35]). This may also contribute to the premature phenotypes found in the zebrafish mutants. Another factor to take into consideration is genetic redundancy. In mammals, there is another closely related TRPV sub-family member, TRPV5. TRPV5 plays similar roles in the transcellular Ca^2+^ transport pathway, although it is mainly expressed in the kidney ([@bib19]). It has been shown that TRPV5 expression in the intestine is elevated in *Trpv6* mutant mice ([@bib63]). In comparison, zebrafish genome has a single trpv6 gene and lacks this genetic redundancy ([@bib57]).

The notion that TRPV6 functions as the primary epithelial Ca^2+^ channel is well supported by findings made in mammalian cells over-expressing TRPV6 ([@bib16]) and by measuring endogenous TRPV6-mediated Ca^2+^ influx in cultured Jurkat T cells and rat cauda epidermal principle cells ([@bib17]; [@bib24]). Fura-2 Ca^2+^ imaging studies in cultured mammalian cells transfected with TRPV6 indicated that this channel is constitutively open ([@bib58]). Although another study failed to detect spontaneous channel activity by patch-clamp recording in cells transfected with TRPV6, a recent study has provided structural and functional evidence that TRPV6 is constitutively active ([@bib39]). Other studies have reported that TRPV6 activity is activated by a reduction in \[Ca^2+^\]~i~ concentration, and inactivated by higher \[Ca^2+^\]~i~ in mammalian cells ([@bib42]; [@bib68]). How TRPV6/Trpv6 channel activity is regulated in vivo is less clear. In this study, we generated a reporter fish line using the high-performance genetic calcium reporter GCaMP7a to measure intracellular Ca^2+^ activity in vivo. GCaMPs has been used for imaging intracellular Ca^2+^ activity in zebrafish neurons ([@bib41]). This approach has alleviated the concern associated with Fura-2 and cell culture systems. Our in vivo Ca^2+^ imaging results showed that the Trpv6 channel is constitutively open in NaR cells in vivo. This conclusion is supported by the facts that genetic deletion of *trpv6* reduced the \[Ca^2+^\]~i~ to undetectable levels and re-expression of Trpv6 restored the \[Ca^2+^\]~i~ levels in NaR cells. Addition of ionomycin did not result in further increase, indicating the endogenous \[Ca^2+^\]~i~ levels are high in these cells. More direct evidence came from the \[Ca^2+^\]~i~ dynamics analysis results. Within minutes after the addition of Trpv6 blockers GdCl~3~ or Ruthenium red, the levels of \[Ca^2+^\]~i~ were significantly reduced. When these drugs were washed out, the \[Ca^2+^\]~i~ signal levels returned to normal levels. It was thought that Ca^2+^ transporting epithelial cells, being continuously challenged by Ca^2+^ traffic from the apical side, maintain low levels of \[Ca^2+^\]~i~ using the cytosolic Ca^2+^ binding protein ([@bib19]). The in vivo imaging findings made in this study challenge this conventional view. We postulate that maintaining high \[Ca^2+^\]~i~ levels in these Ca^2+^ transporting cells is likely beneficial to the organism because it keeps these cells in differentiated state and functioning as Ca^2+^ transporting units. This idea is supported by the fact that treatment of zebrafish with the intracellular Ca^2+^ chelator BAPTA-AM promoted quiescent epithelial cells to proliferate.

Mechanistically, Trpv6 regulates the quiescent state by mediating constitutive Ca^2+^ influx to continuously down-regulating IGF1-receptor-mediated Akt-Tor and Erk signaling ([Figure 6D](#fig6){ref-type="fig"}). This is supported by the findings that 1) genetic deletion of Trpv6 or pharmacological inhibition of Trpv6-mediated Ca^2+^ uptake increased Akt-Tor and pErk signaling activity in an IGF1 receptor-dependent manner; 2) re-expression of Trpv6 in the mutant cells suppressed Akt signaling; and 3) inhibition of the IGF1 receptor, PI3 kinase, Tor, and Mek activity abolished or inhibited NaR cell proliferation in *trpv6*^-/-^ mutant fish. This conclusion is consistent with previous reports that up-regulating of IGF signaling promotes NaR cells to exit the quiescence and re-enter the cell cycle ([@bib34]; [@bib35]). NaR cells are one of the five types of ionocytes originated from a population of epidermal stem cells, which are specified by the expression of p63 (ΔNp63), a direct target of BMP signaling ([@bib1]; [@bib21]; [@bib30]). These epidermal stem cells further develop into Foxi3a/b-activated ionocyte progenitor cells and [keratinocyte](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/keratinocyte) progenitor cells with low Foxi3a/b expression ([@bib20]). Krüppel-like factor 4 (Klf4) plays an important role in maintaining the ionocyte progenitor cell pool by stimulating epidermal cell stem proliferation ([@bib6]). In addition, several hormones, including isotocin, cortisol and stanniocalcin 1, have been implicated in the regulation of the ionocyte progenitor cell pool ([@bib8]; [@bib9]; [@bib65]). Foxi3a/3b form a positive regulatory loop and this loop is critical in specifying ionocyte progenitors to give rise to the 5 types of ionocytes ([@bib4]; [@bib20]; [@bib65]). A hallmark of NaR cells is the expression of Trpv6 ([@bib34]; [@bib44]). The role of Trpv6 and IGF signaling in NaR cell quiescence regulation unraveled in this study differs from the mechanisms acting in epidermal stem cells and ionocyte progenitor cells, and provides novel insights into the regulation of NaR cell development and function.

Using unbiased chemical biology screens, we have identified PP2A as a key effector of TRPV6/Trvp6 in regulating NaR cell quiescence. Inhibition of PP2A by two distinct inhibitors led to elevated Akt signaling and increased epithelial cell proliferation. Importantly, an IGF1 receptor inhibitor abolished these changes. Likewise, CRISPR/Cas9-mediated transient knockdown of PP2A catalytic subunits increased epithelial cell proliferation and Akt signaling. PP2A can activate Akt and Erk signaling at multiple sites in the IGF signaling pathway ([@bib43]). Numerous biochemical studies showing that PP2A can dephosphorylate Akt ([@bib47]; [@bib51]). In several human cancer cell lines, PP2A regulates Shc phosphorylation state and upregulates ERK signaling activity in the IGF1-induced signaling pathway ([@bib69]). Our in vivo findings, together with the in vitro findings indicate that a \[Ca^2+^\]~i~-regulated PP2A isoform(s) likely acts downstream of TRPV6/Trpv6 and regulates the quiescent state in epithelial cells. This is in good agreement with a recent study showing that compromising PP2A activity delays cell cycle exit in *Drosophila* ([@bib54]). The TRPV6-\[Ca^2+^\]~i~-PP2A signaling axis appears to be conserved in human colon carcinoma cells because siRNA-mediated knockdown or inhibition of TRPV6 increased LoVo cell proliferation. Likewise, chelating intracellular Ca^2+^, genetic and pharmacological inhibition of PP2A activity resulted in elevated cell proliferation rate of LoVo cells. The substrate specificity and intracellular distribution of the PP2A holoenzymes are controlled by the B regulatory subunits, which are encoded by a large set of genes classified into four families, that is B, B′, B″, and B″′ ([@bib59]). Recent studies suggest that PR72/130 and PR70, 2 members of the B' family, possess two conserved EF hand motifs (termed EF1 and EF2) and increasing \[Ca^2+^\]~i~ increased the holoenzyme assembly and phosphatase activity ([@bib28]; [@bib36]). Another mechanism involves the action of \[Ca^2+^\]~i~-dependent m-calpain: m-calpain degrades PR72 and PR130 into a 45 kDa fragment ([@bib22]). This fragment, termed as PR45, is resistant to further degradation and exhibits enhanced PP2A activity. These two mechanisms may be related because the calpain-mediated proteolytic activation of PP2A depends on the EF hand integrity ([@bib22]). Future studies are needed to determine whether these mechanisms mediate TRPV6/Trpv6 action in epithelial cells.

Our findings linking the Trpv6-meiated Ca^2+^ uptake to the cellular quiescence regulation have important biomedical implications. Approximately 90% of human cancers arise in epithelial tissues and over-proliferation is one of the cancer hallmarks ([@bib18]). The IGF signaling pathway is one of the most frequently mutated signaling pathways in epithelial tissue-derived cancers, including colon and prostate cancers ([@bib37]). The *IGF2* gene and *IRS2* gene are frequently gained in colon cancer ([@bib3]) and have been proposed as a colorectal cancer 'driver' oncogenes ([@bib13]). TRPV6 gene is frequently up-regulated in prostate, colon, and other cancer tissues ([@bib32]; [@bib48]). At present, it is unclear whether the elevated TRPV6 expression promotes tumor growth or it is an adaptive response ([@bib32]; [@bib48]). Knockdown or overexpression of TRPV6 in cultured cancer cells showed mixed effects in increasing/decreasing proliferation and/or apoptosis ([@bib10]; [@bib31]; [@bib32]; [@bib49]; [@bib52]). Future studies are needed to clarify the role of TRPV6-\[Ca^2+^\]~i~-PP2A in prostate and colon cancer initiation and progression and its relationship to IGF signaling.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                               Designation                                                                         Source or\                                                            Identifiers                                                      Additional\
  (species) or\                                                                                                                   reference                                                                                                                              information
  resource                                                                                                                                                                                                                                                               
  ------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------
  Strain, strain background (*Danio rerio*)   *Tg(igfbp5a:GFP)*                                                                   Pubmed ID: [28515443](https://www.ncbi.nlm.nih.gov/pubmed/28515443)   ZFIN ID: ZDB-TGCONSTRCT-170830--2                                

  Strain, strain background (*Danio rerio*)   *trpv6*^-/-^; *Tg(igfbp5a:GFP)*                                                     This paper                                                                                                                             CRISPR/Cas9-mediated knockout

  Strain, strain background (*Danio rerio*)   *Tg(igfbp5a:GCaMP7a)*                                                               This paper                                                                                                                             Tol2-mediated transgenesis

  Strain, strain background (*Danio rerio*)   *trpv6*^-/-^                                                                        This paper                                                                                                                             CRISPR/Cas9-mediated knockout

  Strain, strain background (*Danio rerio*)   *trpv6*^-/-^; *Tg(igfbp5a:GCaMP7a)*                                                 This paper                                                                                                                             Cross *trpv6*^-/-^ with *Tg (igfbp5a:GCaMP7a)*

  Genetic reagent (*Homo sapiens*)            Human TRPV6 siRNA                                                                   Pubmed ID: [19270724](https://www.ncbi.nlm.nih.gov/pubmed/19270724)                                                                    GACUCUCUAUGACCUCACA

  Genetic reagent                             Mission siRNA Universal Negative Control \#1                                        Sigma                                                                 Catalog no.: SIC001-10nmol                                       

  Cell line (*Homo sapiens*)                  LoVo                                                                                ATCC                                                                  RRID:[CVCL_039](https://scicrunch.org/resolver/CVCL_039)         

  Cell line (*Homo sapiens*)                  HEK293                                                                              ATCC                                                                  RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)       

  Antibody                                    Phospho-Akt (Ser473) (Rabbit monoclonal)                                            Cell Signaling Technology                                             RRID:[AB_2315049](https://scicrunch.org/resolver/AB_2315049)     1:200

  Antibody                                    Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Rabbit monoclonal)                    Cell Signaling Technology                                             RRID:[AB_2315112](https://scicrunch.org/resolver/AB_2315112)     1:200

  Antibody                                    Phospho-S6 Ribosomal Protein (Ser235/236) (Rabbit monoclonal)                       Cell Signaling Technology                                             RRID:[AB_2181037](https://scicrunch.org/resolver/AB_2181037)     1:200

  Antibody                                    Peroxidase-conjugated AffiniPure Donkey Anti-Rabbit IgG (H+L) (Donkey polyclonal)   Jackson ImmunoResearch Laboratories                                   RRID:[AB_10015282](https://scicrunch.org/resolver/AB_10015282)   1:400

  Antibody                                    Cy3 AffiniPure Goat Anti-Rabbit IgG (H+L) (Goat polyclonal)                         Jackson ImmunoResearch Laboratories                                   RRID:[AB_2338006](https://scicrunch.org/resolver/AB_2338006)     1:300

  Antibody                                    Anti-digoxigenin POD-conjugate (Sheep polyclonal)                                   Roche                                                                 RRID:[AB_51450](https://scicrunch.org/resolver/AB_51450)         1:500

  Recombinant DNA reagent                     PP2Ac-L199P                                                                         Pubmed ID: [16224536](https://www.ncbi.nlm.nih.gov/pubmed/16224536)                                                                    

  Recombinant DNA reagent                     PP2Ac-H118N                                                                         Pubmed ID: [16224536](https://www.ncbi.nlm.nih.gov/pubmed/16224536)                                                                    

  Chemical compound, drug                     BMS-754807                                                                          Active Biochemicals Co.                                               Catalog no.: A-1013                                              

  Chemical compound, drug                     Wortmannin                                                                          Cell Signaling Technology                                             Catalog no.: 9951                                                

  Chemical compound, drug                     Rapamycin                                                                           Calbiochem                                                            Catalog no.: 553210                                              

  Chemical compound, drug                     U0126                                                                               Cell Signaling Technology                                             Catalog no.: 9903                                                

  Chemical compound, drug                     Okadaic acid                                                                        Santa Cruz Biotechnology                                              Catalog no.: sc3513                                              

  Chemical compound, drug                     Calyculin A                                                                         Alonmone                                                              Catalog no.: C-100                                               

  Chemical compound, drug                     Gadolinium (III) chloride                                                           Sigma-Aldrich                                                         Catalog no.: 439770                                              

  Chemical compound, drug                     Ruthenium red                                                                       Sigma-Aldrich                                                         Catalog no.: R2751                                               

  Chemical compound, drug                     Alizarin red S                                                                      Sigma-Aldrich                                                         Catalog no.: A5533                                               

  Chemical compound, drug                     Propidium iodide                                                                    Sigma-Aldrich                                                         Catalog no.: P4170                                               

  Chemical compound, drug                     Fura-2, AM, cell permeant                                                           Invitrogen                                                            Catalog no.: F1221                                               

  Peptide, recombinant protein                Cas9 protein with NLS                                                               PNA Bio                                                               Catalog no.: CP01                                                

  Software, algorithm                         GraphPad Prism                                                                                                                                            RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemicals and reagents {#s4-1}
----------------------

All chemical reagents were purchased from Fisher Scientific (Pittsburgh, PA) unless stated otherwise. Restriction enzymes were bought from New England Bio Labs (Beverly, MA).

Zebrafish husbandry {#s4-2}
-------------------

Fish were raised following standard zebrafish husbandry guideline ([@bib61]). Embryos were obtained by natural cross and staged following [@bib26]. E3 embryo rearing solution (containing 0.33 mM \[Ca^2+^\]) was prepared as reported ([@bib61]). Two additional embryo rearing solutions containing 0.2 mM \[Ca^2+^\] (i.e. normal \[Ca^2+^\] solution) or 0.001 mM \[Ca^2+^\] (i.e. low \[Ca^2+^\] solution) were made following previously reported formula ([@bib12]). To inhibit pigmentation, 0.003% (w/v) N-phenylthiourea (PTU) was added in some experiments. All experiments were conducted in accordance with the guidelines approved by the University of Michigan Institutional Committee on the Use and Care of Animals.

Generation of *trpv6^-/-^* fish lines using CRISPR/Cas9 {#s4-3}
-------------------------------------------------------

The sgRNA targeting *trpv6* (5'-GGGCTCGTTGATGAGCTCCG-3') was designed using CHOPCHOP (<http://chopchop.cbu.uib.no/>). The sgRNA (30 ng/μl) was mixed with Cas9 protein (700 ng/μl) and co-injected into *Tg(igfbp5a:GFP)* or wild-type embryos at the one-cell stage as described ([@bib64]). After confirming indels by PCR followed by hetero-duplex assay using a subset of F0 embryos, the remaining F0 embryos were raised to adulthood and crossed with *Tg(igfbp5a:GFP)* or wild-type fish. F1 fish were raised to the adulthood and genotyped. After confirming indels by DNA sequencing, the heterozygous F1 fish were intercrossed to generate F2 fish.

Transient knockdown of *ppp2cs* {#s4-4}
-------------------------------

Three sgRNAs targeting *ppp2cs* were designed using CHOPCHOP (<http://chopchop.cbu.uib.no/>). Their sequences are: *ppp2ca*-sgRNA: 5'-GTTCCATAAGATCGTGAAAC-3'; *ppp2cb*-sgRNA: 5'-GAGCGTTCTCACTTGGTTCT-3'; *ppp2ca2*-sgRNA: 5'-GACGAAGGAGTCGAATGTGC-3'. sgRNAs (30 ng/μl) were mixed with Cas9 protein (700 ng/μl) and co-injected into *Tg(igfbp5a:GFP)* or wild type embryos at the one-cell stage as reported ([@bib64]). A subset of injected embryos was pooled, DNA isolated, and analyzed by PCR followed by hetero-duplex assays as reported ([@bib35]). After confirming the indels, the remaining injected embryos were used for experiments.

Genotyping {#s4-5}
----------

To isolate genomic DNA, pooled embryos or individual adult caudal fin were incubated in 50 μl NaOH (50 mM) at 95°C for 10 min and neutralized by adding 5 μl 1 M Tris-HCl (pH 8.0). PCR was performed using the following primers: *trpv6*-gt-f, 5'-TGACATTGTGTGTGTTTGTTGC-3'; *trpv6*-gt-r, 5'-GTGAAGGGCTGTTAAACCTGTC-3'*; trpv6*-HMA-f, 5'- GCAGCGGTGGCTTTAATGAAT-3'; *trpv6*-HMA-r, 5'- AAACCTGTCAATCAGAGCACAC-3'; *ppp2ca*-gt-f, 5'- TCACCATCAGTGCATGTCAATA-3'; *ppp2ca*-gt-r, 5'- CTCGATCCACATAGTCTCCCAT-3'; *ppp2cb*-gt-f, 5'- TGGATGATAAAGCGTTTACGAA-3'; *ppp2cb*-gt-r, 5'- ACGTTACACATTGCTTTCATGC-3'; *ppp2ca2*-gt-f, 5'-CTGATGGTTGTGATGCTGTTTT-3'; *ppp2ca2*-gt-r, 5'-CGGTTTCCACAGAGTAATAGCC-3'.

Morphology analysis {#s4-6}
-------------------

Body length, defined as the curvilinear distance from the head to the end of caudal tail, was measured. Alizarin red staining was performed following a published protocol ([@bib14]). Images were captured with a stereomicroscope (Leica MZ16F, Leica, Wetzlar, Germany) equipped with a QImaging QICAM camera (QImaging, Surrey, BC, Canada).

Whole-mount in situ hybridization, and immunostaining {#s4-7}
-----------------------------------------------------

For whole mount immunostaining or in situ hybridization analysis, zebrafish larvae were fixed in 4% paraformaldehyde, permeabilized in methanol, and analyzed as described previously ([@bib12]). For double color in situ hybridization and immunostaining, mCherry mRNA signal was detected using anti-DIG-POD antibody (Roche), followed by Alexa 488 Tyramide Signal Amplification (Invitrogen). After in situ hybridization, the stained larvae were washed in 1X PBST and incubated with phosphorylated-Akt antibody overnight at 4°C and then stained with a Cy3-conjugated goat anti-rabbit immunoglobulin G antibody (Jackson ImmunoResearch). Fluorescent images were acquired using a Nikon Eclipse E600 Fluorescence Microscope with PMCapture Pro six software.

Plasmid and BAC constructs {#s4-8}
--------------------------

The ORF of zebrafish Trpv6 was amplified by PCR using five dpf zebrafish cDNA as template and cloned into pEGFPN1 using the following primers: BglII-zftrpv6-F, 5'-atatAGATCTcgccaccATGCCACCCGCCATATC-3'; no stop-zftrpv6-ca-SalI-R, 5'- TACCGTCGACcaGAGAAACTTGAAATTggggcaatc-3'; Trpv6D539A was engineered by site-directed mutagenesis using the following primers: zTrpv6_D539A_f, 5'-GGTCAGATTGCCTTGCCAGTGGA-3'; zTrpv6_D539A_r, 5'- TCCACTGGCAAGGCAATCTGACC-3'. Human TRPV6 ORF was sub-cloned into pEGFPN1 using the following primers: 5'-atatCTCGAGcgccaccATGGGTTTGTCACTG-3'; 5'- TACCGTCGACcaGATCTGATATTCC-3'. EGFP sequence in those vectors was replaced by mCherry sequence from pmCherry-C1 vector using the following primers: AgeI-mCherry-F, 5'- caACCGGTCGCCACCATGGTGAGCAAGGGC-3'; mCherry-NotI-stop-r, 5'- TCGCGGCCGCCTACTTGTACAGCTCGTCC-3'. Wild-type zebrafish Trpv6 and Trpv6D539A tagged with mCherry were then inserted into the *igfbp5aBAC* construct to replace the *igfbp5a* coding sequence from the start codon to the end of the first exon through homologous recombination as reported ([@bib34]). The primers are: *igfbp5a-zTrpv56*-f, 5'- GTTTTGCCATTTCAAAGCTGGTGAAATAGGTGTTCTACAGTAGGACGATGCCACCCGCCATATCTGGTGAA-3' and igfbp5a-pEGFP-C3-Kan-R, . The resulted BAC DNA was validated by sequencing. The validated BAC DNA and Tol2 mRNA were mixed and injected into 1 cell stage *trpv6^-/-^; Tg(igfbp5a:GFP)* embryos. Cells co-expressing mCherry and GFP at five dpf were identified and scored using a reported scoring system ([@bib35]). PP2Ac^L199P^ and PP2Ac^H118N^ were kind gifts from Dr. George Tsokos, Harvard Medical School. They were subloned into pIRES-mCherry vector using the following primers: EcoRI-PP2A-f: 5'-ccgGAATTCATGGACGAGAAGGTGTTCAC-3', BamHI-PP2A-r: 5'-cgcGGATCCTTACAGGAAGTAGTCTGGGG-3' and used in cell transfection.

Generation of the *Tg(igfbp5a:GCaMP7a)* fish line {#s4-9}
-------------------------------------------------

*GCaMP7a* DNA was cloned into pEGFPN1 to replace the EGFP sequence using the following primers: BamHI-HA-F, 5'- cgcggatccATGGCATACCCCTACGACG-3'; GCaMP7a-stop-NotI-R, 5'- atttgcggccgcTTACTTAGCGGTCATCATC-3'. The *BAC*(*igfbp5a:GCaMP7a*) construct was generated following a published protocol ([@bib34]). The following primers were used to amplify the GCaMP7a cassette sequence: *igfbp5a*\_GCaMP7a_fw, 5′- GTTTTGCCATTTCAAAGCTGGTGAAATAGGTGTTCTACAGTAGGACGATGGCATACCCCTACGACGTGCCCGAC −3′ and igfbp5a-pEGFP-C3-kan-R The resulted *BAC(igfbp5a:*GCaMP7a) was validated by sequencing. *BAC(igfbp5a:GCaMP7a)* DNA and *Tol2* mRNAs were mixed and injected into zebrafish embryos at one-cell stage. The F0 embryos were screened at 72 hpf by checking GCaMP7a responses to high or low \[Ca^2+^\] solutions. GCaMP7a-positive F0 embryos were raised and crossed with wild-type fish to obtain F1 individuals. F2 fish were generated by crossing F1 fish.

Live GCaMP7a imaging {#s4-10}
--------------------

Zebrafish larvae were anesthetized using normal \[Ca^2+^\] embryo solution supplemented with 0.168 mg/ml tricaine. They were mounted in 0.3% low-melting agarose gel and immersed in 1 ml normal \[Ca^2+^\] solution. A Leica TCS SP8 confocal microscope equipped with the HC PL APO 93X/1.30 GLYC was used for imaging and LAS X and Image J were used for image analysis.

RT-qPCR {#s4-11}
-------

Zebrafish larvae raised in E3 embryo rearing solution were transferred to normal or low \[Ca^2+^\] embryo solution from three dpf. Two days later, caudal fin was clipped for genotyping. The larvae of the same genotype and treatment group were pooled and RNA was isolated. Reverse transcription reaction was performed using M-MLV (Invitrogen) oligo(dT)~18~ oligos primer. qPCR was carried out using SYBR Green (Bio-Rad). Primers for qPCR are: *trpv6*-qPCR-F: 5'- GGACCCTACGTCATTGTGATAC-3', *trpv6*-qPCR-R: 5'- GGTACTGCGGAAGTGCTAAG-3', *igf1ra*-qPCR-F: 5'- CGTACCTCAATGCCAACAAG-3', *igf1ra*-qPCR-R: 5'- TAGGGCTGTTCGGCTAATGT-3', *igf1rb*-qPCR-F: 5'- AAACTTGGGACCAGGGAACT-3', *igf1rb*-qPCR-R: 5'- ATCTTCTCCCGCTCCACTTC-3'. *18s*-qPCR-F: 5'- AATCGCATTTGCCATCACCG-3', *18s*-qPCR-R: 5'- TCACCACCCTCTCAACCTCA-3'.

Cell culture {#s4-12}
------------

Human embryonal kidney cells (HEK293) and human LoVo conlon cancer cells were obtained from American Type Tissue Collection (ATCC). Cell identity was authenticated by short tandem repeat (STR) analysis. Cells used were periodically tested for *Mycoplasma* contamination. HEK293 and LoVo cells were cultured in DMEM or DMEM/F12 supplemented with 10% FBS, penicillin and streptomycin in a humidified-air atmosphere incubator containing 5% CO~2~.

Fura-2 imaging and electrophysiology recording {#s4-13}
----------------------------------------------

HEK293 cells were plated onto 24-mm cover glass coated with L-polylysine and transfected with 0.3 µg of plasmid DNA using Lipofectamine 2000. Twenty-four hours after the transfection, the cover glass was mounted on an imaging chamber and washed with calcium-free Krebs-Ringer HEPES (KRH) solution (118 mM NaCl, 4.8 mM KCl, 1 mM MgCl~2~, 5 mM D-glucose, and 10 mM HEPES, pH = 7.4). Fura-2 loading was performed following a published method ([@bib27]). Successfully transfected cells were chosen by mCherry expression. Their cytosolic Ca^2+^ levels were recorded by an EasyRatio Pro system (PTI) at two different wavelengths (340 nm and 380 nm). The Fura-2 ratio (F340/F380) was used to determine changes in intracellular \[Ca^2+^\]~i~. At least 50 cells were measured in each slide. Patch clamp recordings were performed at room temperature ([@bib60]). The internal pipette solution contained (in mM): Aspartate-Cs 145, NaCl 8, MgCl~2~ 2, HEPES 10, EGTA 10, Mg-ATP 2, pH 7.2. Normal external solution contained (in mM): NaCl 135, KCl 6, MgCl~2~ 1.2, HEPES 10, Glucose 12, pH 7.4, supplemented with 10 mM CaCl~2~ or 30 mM BaCl~2~. For measuring Ca^2+^ currents, cells were perfused with the normal external solution at first and then switched to solutions as indicated. The DVF solution contains (in mM): NaCl 150, EDTA 10, HEPES 10, pH 7.4. Solutions with different concentration of Ca^2+^ contains (in mM): NaCl 150, HEPES 10, Glucose 12, pH 7.4, supplemented with 0 to 10 mM CaCl~2~ as indicated.

Flowcytometry analysis and MTT assay {#s4-14}
------------------------------------

Human LoVo cells were washed three times with serum-free medium (SFM) and starved in SFM for 12 hr. The cells were then stimulated with 2% FBS medium, with or without inhibitors. Forty-eight hours later, cell cycle analysis was performed using Attune Acoustic Focusing cytometer (Applied Biosystems, Life Technologies) after propidium iodide staining ([@bib35]). For siRNA transfection, 100 pmol siRNA and 1.5 µl Lipofectamine RNAiMAX (Invitrogen) was used in each well in 24-well tissue culture plates. For plasmid transfection, 2 µg plasmid and 2 µl Lipofectamine 3000 (Invitrogen) were used in in each well in 24-well tissue culture plates. Six hrs post transfection, cells were grown in complete media containing 10% FBS. There were washed three times with SFM and synchronized by incubation in SFM for 12 hr. The synchronized cells were stimulated with 2% FBS-containing medium for 48 hr and subjected to cell cycle analysis or MTT assay. For MTT assay, 5 mg/ml MTT (Invitrogen) stock solution was diluted with 2% FBS-containing medium and cells were stained for 4 hr at 37°C before dissolving using DMSO. Absorbance at 540 nm was read by a microplate reader (Tecan).

Statistical analysis {#s4-15}
--------------------

Values are shown as Mean ± standard error of the mean (SEM). Statistical significance between experimental groups was determined using one-way ANOVA followed by Tukey's multiple comparison test or student t-test. Chi-square test was used to analyze the association between two categorical variables. Statistical significances were accepted at p\<0.05 or greater.
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Summary:

In this study, using zebrafish epithelial cells, the authors provide evidence that Trpv6 mediates constitutive epithelial Ca^2+^ influx to maintain the quiescent state. This is in agreement with the notion that TRPV6 is indispensable for epithelial cell Ca^2+^ uptake and maintenance of body Ca^2+^ homeostasis. By using genetic or pharmacological deletion of the TRpv6 channel, it was established that the Ca^2+^ conductance function of TRPV6 serves as a barrier in the quiescence to proliferation transition decision in zebrafish NaK-ATPase-rich ionocytes (NaR cells). Re-introduction of the channel restored quiescence in NaR cells. The study then investigated the mechanisms and proposed that Trpv6-mediated calcium flux acts through suppression of the IGF-1-Akt-Tor signaling pathway via the phosphatase 2A (PP2A). A chemical inhibitor screen was used to identify PP2A), and PP2A inhibition increased NaR cell proliferation as well as the phosphorylation of Akt. Furthermore, an IGF-1R kinase inhibitor reversed both the quiescence-proliferation transition as well as the phosphorylation of Akt caused by the inhibition of PP2A. The authors also suggest that this mechanism is conserved in in human colon cancer cells where Trpv6-mediated calcium influx was suggested to activate the PP2A phosphatase and thereby down regulate IGF-1 and Akt signaling.

Overall, this is a novel and well-presented study that greatly benefits from the lack of genetic redundancy within the TRP family in zebrafish.

The following concerns and suggestions should be addressed.

Essential revisions:

1\) The authors should show whether the 2-day long, low \[Ca^2+^\] treatment affects the expression level of TRPV6 in the NaR cells of wild-type or heterozygous TRPV6 fish.

2\) It is stated that \"TRPV6-mediated Ca^2+^ influx or current has not been recorded in vivo or even in primary epithelial cells (Fecher-Trost, Wissenbach, and Weissgerber, 2017).\" However, constitutively active Ca^2+^ current (endogenous) with characteristics that match the epithelial calcium channel TRPV6 have been previously measured in the epithelial principal cells of the rat epididymis (please see Gao et al., 2016). Endogenous TRPV6 currents have also recently been recorded in Jurkat T cells in another study by Kever et al., 2019.

3\) The third paragraph of the Discussion puts a question mark on the constitutive activity of the TRPV6 channel overexpressed in mammalian cells and rather speaks for the store-depletion based activation of TRPV6. But it has already been well documented by different and more recent patch-clamp and calcium imaging studies that TRPV6 is constitutively active and its activation does not depend on the store content. See for example the study of McGoldrick et al., 2018, where constitutive currents were recorded in the human TRPV6 transfected HEK293 cells. The Discussion text should be updated accordingly to cover the up-to-date published information on TRPV6 constitutive activity.

4\) Several studies have dissected out the molecular pathways of how epithelial cells (including NaR cells) are differentiated from the stem cells and progenitor cells through the regulations by some transcription factors (Foxi3a/b, Gcm2, Klf4, etc.) (Chen et al., 2019; Hsiao et al., 2007; Chang et al., 2009). Some hormones (isotocin, stanniocalain, etc.) were found to positively or negatively regulate the proliferation and differentiation of the mature NaR cells from stem cells and/or progenitor cells (Chou et al., 2011; Chou et al., 2015). I am wondering how much these pathways participate in the epithelial homeostasis. Is there any possible relationship between these pathways and the present proposed signaling in terms of epithelial homeostasis? Can we look at the epithelial homeostasis without considering any effects from the stem cells and/or progenitor cells?

5\) The rationale for linking the TRPV6 phenotype with IGF-1 signaling through the Akt/mTOR pathway in a PP2A-dependent manner is not entirely supported by the data presented on the actions of inhibitors of these pathways.

6\) To establish a more direct link, it would be worthwhile to know whether the presence or absence of TRPV6 in WT, heterozygous or mutant fish has an impact on the expression levels of IGF-1R.

7\) Activation of mitogen activated kinase pathways (MAPK/Erks) by mitogens or growth factor including IGF-1 is generally associated with cell cycle progression. It is surprising that the activation/status of MAPK pathways was not tested or discussed. Demonstration of Akt or TOR activation is not sufficient to conclude that this pathway (activated by IGF-1) is sufficient to drive transition from quiescence to proliferation.

8\) The IGF-1R kinase inhibitor BMS is used in a number of experiments, but it is difficult to appreciate what overall effect it has on fish embryos. In Figure 3C there appears to be no affect in WT embryos while BMS suppresses the increase in pAkt observed in TRP6 mutant embryos. Some inhibition of Akt in WT embryos might be expected if IGF-1R is inhibited in WT embryos. Would it be possible to measure IGF-1R activity (e.g. autophosphorylation) to support the observations in Figure 3? Could other IGF-1R activated pathways (e.g. MAPK as discussed above) be tested to support the conclusions?

9\) It is stated that, \"Treatment of the mutant fish with BMS- 754807, an IGF1 receptor inhibitor, abolished the quiescence to proliferation transition (Figure 3I- 3J)\". It would be advisable to explicitly mention here that \"However, IGF1 receptor inhibition in heterozygous or WT TRPV6 fish, did not show any significant effect on the NaR cell proliferation.\"

10\) The role of PP2A in NaR cell proliferation and of PP2A in regulating IGF-1R-dependent Akt activity is supported by the inhibitory effects of Okadaic acid and Calyculin. However, the effects of PP2A inhibition on cell proliferation could be independent of Akt. PP2A has well-documented functions in adhesion/growth factor signaling and Shc phosphorylation leading to MAPK activation that should be considered.

11\) The experiments with LOVO cells are important to support a role for TRPV6 in human epithelial cells proliferation. But, more data is required to support the data presented in Figure 5F. This includes cell cycle analysis profiles (G1, S, G2/M) as well as some indication of cell viability, cell number/proliferation in the presence and absence of the inhibitors after 48 hours. Moreover, controls showing the on-target effects of the inhibitors under the specific cell culture conditions are necessary.

10.7554/eLife.48003.sa2

Author response

> Essential revisions:
>
> 1\) The authors should show whether the 2-day long, low \[Ca^2+^\] treatment affects the expression level of TRPV6 in the NaR cells of wild-type or heterozygous TRPV6 fish.

Following this suggestion, we performed additional experiments. The results, presented in Figure 3---figure supplement 1A, showed that 2-day low \[Ca^2+^\] treatment increased Trpv6 mRNA levels in wild-type fish and heterozygous fish, part of an adaptive response in Ca^2+^ homeostasis reported previously (Liu et al., 2017). This increase in *trpv6* mRNA levels was abolished in *trpv6*^-/-^ mutant (Figure 3---figure supplement 1A), likely due to non-sense mRNA-mediated decay of mutant *trpv6* mRNA.

2\) It is stated that \"TRPV6-mediated Ca^2+^ influx or current has not been recorded in vivo or even in primary epithelial cells (Fecher-Trost, Wissenbach, and Weissgerber, 2017).\" However, constitutively active Ca^2+^ current (endogenous) with characteristics that match the epithelial calcium channel TRPV6 have been previously measured in the epithelial principal cells of the rat epididymis (please see Gao et al., 2016). Endogenous TRPV6 currents have also recently been recorded in Jurkat T cells in another study by Kever et al., 2019.

We thank the reviewer(s) for bringing our attention to these publications. In the revised manuscript, we have changed the sentences to: "The notion that TRPV6 functions as the primary epithelial Ca^2+^ channel is well supported by in vitro findings made in mammalian cells over-expressing TRPV6 (Fecher-Trost, Wissenbach, and Weissgerber, 2017) and by measuring endogenous TRPV6-mediated Ca^2+^ influx in cultured Jurkat T cells and rat cauda epidermal principle cells (Kever et al., 2019; Gao et al., 2016)".

> 3\) The third paragraph of the Discussion puts a question mark on the constitutive activity of the TRPV6 channel overexpressed in mammalian cells and rather speaks for the store-depletion based activation of TRPV6. But it has already been well documented by different and more recent patch-clamp and calcium imaging studies that TRPV6 is constitutively active and its activation does not depend on the store content. See for example the study of McGoldrick et al., 2018, where constitutive currents were recorded in the human TRPV6 transfected HEK293 cells. The Discussion text should be updated accordingly to cover the up-to-date published information on TRPV6 constitutive activity.

We agree that more recent studies showing *TRPV6* is constitutively active. We have changed this part to: "Fura-2 Ca^2+^ imaging studies in cultured mammalian cells transfected with TRPV6 indicated that this channel is constitutively open (Vennekens et al., 2000). Although another study failed to detect spontaneous channel activity by patch-clamp recording in cells transfected with TRPV6, a recent study has provided structural and functional evidence that TRPV6 is constitutively active (McGoldrick et al., 2018)".

> 4\) Several studies have dissected out the molecular pathways of how epithelial cells (including NaR cells) are differentiated from the stem cells and progenitor cells through the regulations by some transcription factors (Foxi3a/b, Gcm2, Klf4, etc.) (Chen et al., 2019; Hsiao et al., 2007; Chang et al., 2009). Some hormones (isotocin, stanniocalain, etc.) were found to positively or negatively regulate the proliferation and differentiation of the mature NaR cells from stem cells and/or progenitor cells (Chou et al., 2011; Chou et al., 2015). I am wondering how much these pathways participate in the epithelial homeostasis. Is there any possible relationship between these pathways and the present proposed signaling in terms of epithelial homeostasis? Can we look at the epithelial homeostasis without considering any effects from the stem cells and/or progenitor cells?

In the revised manuscript, we have added a paragraph discussing published work on the developmental origin of NaR cells and the roles of p63, Foxi3a/3b, *Gcm2,* Klf4, isotocin, cortisol, and stanniocalcin in regulating epidermal stem cells and ionocyte progenitor cells (Discussion, fourth paragraph). All the above mentioned papers are now cited. We pointed out that the previously reported mechanisms are different from the role of Trpv6-regulated IGF signaling discovered in this study. Trpv6 expression is a hallmark of NaR cells. The Trpv6 acts in NaR cells to maintain cellular quiescent state and prevent NaR cell proliferation (Pan et al., 2005; Dai et al., 2014) (see the aforementioned paragraph). Our findings have added yet another layer of regulation in NaR cell biology.

> 5\) The rationale for linking the TRPV6 phenotype with IGF-1 signaling through the Akt/mTOR pathway in a PP2A-dependent manner is not entirely supported by the data presented on the actions of inhibitors of these pathways.

We have obtained additional data linking the TRPV6 phenotype with IGF signaling. Our data showed that i) Akt and Tor signaling activity was activated in *trpv6*^-/-^ larvae kept in the normal \[Ca^2+^\] embryo medium, while the levels of phospho-Akt in the siblings were minimal (Figure 3B, 3C; Figure 3---figure supplement 2); ii) Blocking Trpv6 channel activity by GdCl~3~ and Ruthenium red increased phospho-Akt levels and NaR cell proliferation in the wild-type fish (Figure 3---figure supplement 3 and Figure 2---figure supplement 2, iii) inhibition of IGF1 receptor abolished the quiescence to proliferation transition in mutant larvae, while it did not have such effect in the wild-type and heterozygous siblings (Figure 3F); and iv) Treatment of *trpv6*^-/-^ mutant fish with PI3 kinase inhibitor Wortmannin and Tor inhibitor Rapamycin abolished NaR cell proliferation transition in mutant larvae, while they had no effects in the siblings (Figure 3G-3I). These data argue strongly that loss of Trpv6 increases NaR cell proliferation via the activation of IGF -Akt-Tor signaling. Our new data also showed that the MAP kinase pathway is also involved (see details in \#7).

> 6\) To establish a more direct link, it would be worthwhile to know whether the presence or absence of TRPV6 in WT, heterozygous or mutant fish has an impact on the expression levels of IGF-1R.

Following this suggestion, we measured the expression levels of IGF1 receptor genes by RT-qPCR. Zebrafish has two IGF1 receptor genes, i*gf1ra* and *igf1rb*, due to a teleost specific genome wide duplication event (Maures and Duan, 2002; Schlueter et al., 2006). The data, shown in Figure 4---figure supplement 1B and 1C, showed that the *igfr1a* and *igfr1b* mRNA levels were comparable between *trpv6^-/-^*larvae andsiblings. These results are consistent with our conclusion that Trpv6 suppresses IGF signaling by mediating Ca^2+^ influx and activating PP2A in NaR cells. It is in good agreement with the data presented in Figure 4---figure supplement 4, showing that inhibition of the IGF1 receptor did not change intracellular \[Ca^2+^\]~i~ in NaR cells.

> 7\) Activation of mitogen activated kinase pathways (MAPK/Erks) by mitogens or growth factor including IGF-1 is generally associated with cell cycle progression. It is surprising that the activation/status of MAPK pathways was not tested or discussed. Demonstration of Akt or TOR activation is not sufficient to conclude that this pathway (activated by IGF-1) is sufficient to drive transition from quiescence to proliferation.

We thank the reviewers for this suggestion. We have carried out additional experiments to address this concern. The new results, presented in Figure 3E, 3I and Figure 3---figure supplement 4, showed that pErk activity was elevated in *trpv6^-/-^*larvae compared with the siblings. The pErk signal was reduced by adding the Mek inhibitor U0126. Furthermore, U0126 treatment significantly decreased NaR cell proliferation in mutant larvae, while it did not have such effect in wild-type and heterozygous siblings. These new data suggest that the MAPK/Erk pathway is also involved in mediating Trpv6 action.

> 8\) The IGF-1R kinase inhibitor BMS is used in a number of experiments, but it is difficult to appreciate what overall effect it has on fish embryos. In Figure 3C there appears to be no affect in WT embryos while BMS suppresses the increase in pAkt observed in TRP6 mutant embryos. Some inhibition of Akt in WT embryos might be expected if IGF-1R is inhibited in WT embryos. Would it be possible to measure IGF-1R activity (e.g. autophosphorylation) to support the observations in Figure 3? Could other IGF-1R activated pathways (e.g. MAPK as discussed above) be tested to support the conclusions?

We have previously shown that treatment of zebrafish embryos with IGF1 receptor kinase inhibitors resulted in reduced growth and slower developmental delay and so did morpholino-based knockdown and genetic inhibition of IGF1 receptor by a dominant negative approach (Schluter et al., 2007, Cell Death Diff. 14:1095; Kamei et al., 2011, Development, 138: 777-786). The current study focused on the local action of IGF signaling in NaR cells. Previous studies suggested that when zebrafish embryos are grown in embryo media containing normal concentrations of \[Ca^2+^\], NaR cells are maintained in a quiescent state characterized by very low cell division rate and undetectable Akt-Tor activity. Low \[Ca^2+^\] stress increases the Akt-Tor activity exclusively in an IGF1 receptor-dependent manner in these cells and this in turn promotes quiescent NaR cells to re-enter the cell cycle (Dai et al., 2014; Liu et al., 2017). While the IGF1 receptor genes are widely expressed in many cell types, IGF binding protein 5a (Igfbp5a) is specifically expressed in NaR cells (Dai et al., 2010; 2014; Liu et al., 2017). Genetic deletion of *igfbp5a* blunted the low Ca^2+^ stress-induce IGF-PI3 kinase-Akt-Tor and NaR cell proliferation. Reintroducing Igfbp5a, but not its ligand binding--deficient mutant, restored NaR cell reactivation (Liu et al., 2018).

In this study, we showed that the pAkt and pErk signaling activity was activated in NaR cells in two independent *trpv6^-/-^*lines (but not in their wild-type and heterozygous siblings) when these fish were kept in embryo media containing normal concentrations of \[Ca^2+^\] (Figure 3B, 3C, and 3E). Addition of the IGF-1R inhibitor BMS abolished pAkt and pErk signaling in NaR cells in *trpv6^-/-^*fish, while they had no effect in siblings (Figure 3B, 3C). These and other evidence have led to the model that Trpv6 suppresses IGF signaling in NaR cells by mediating Ca^2+^ influx and activating PP2A, which down-regulates IGF signaling in the cytosol (Figure 6F). We agree that it would be ideal to directly measure IGF-1R activity in NaR cells. Unfortunately, available mammalian phospho-IGF1R antibodies did not yield specific signals in zebrafish larvae (Dai et al., 2014). Since there are \~ 50 NaR cells in each larva under basal conditions, co-IP with a total IGF1 receptor antibody and an anti-tyrosine antibody is difficult. Our model is consistent with previous biochemical studies showing that PP2A can activate Akt and Erk signaling at multiple sites in the IGF signaling pathway (O'Conner, 2003). Our conclusion is also supported by the fact that inhibition of the IGF1 receptor and PP2A did not change intracellular \[Ca^2+^\]~i~ in NaR cells (Figure 4---figure supplement 4; Figure 5---figure supplement 2).

> 9\) It is stated that, \"Treatment of the mutant fish with BMS- 754807, an IGF1 receptor inhibitor, abolished the quiescence to proliferation transition (Figure 3I- 3J)\". It would be advisable to explicitly mention here that \"However, IGF1 receptor inhibition in heterozygous or WT TRPV6 fish, did not show any significant effect on the NaR cell proliferation.\"

Changed as suggested. Thank you.

> 10\) The role of PP2A in NaR cell proliferation and of PP2A in regulating IGF-1R-dependent Akt activity is supported by the inhibitory effects of Okadaic acid and Calyculin. However, the effects of PP2A inhibition on cell proliferation could be independent of Akt. PP2A has well-documented functions in adhesion/growth factor signaling and Shc phosphorylation leading to MAPK activation that should be considered.

We agree. The new data on the role of pErk indicate that PP2A may down-regulate IGF signaling via Akt-dependent and independent mechanisms (Figure 5C). In the revised manuscript, we have added discussions on the possibilities that PP2A may affect IGF signaling through regulating Shc phosphorylation state and increasing MAPK activity (Discussion, fifth paragraph).

> 11\) The experiments with LOVO cells are important to support a role for TRPV6 in human epithelial cells proliferation. But, more data is required to support the data presented in Figure 5F. This includes cell cycle analysis profiles (G1, S, G2/M) as well as some indication of cell viability, cell number/proliferation in the presence and absence of the inhibitors after 48 hours. Moreover, controls showing the on-target effects of the inhibitors under the specific cell culture conditions are necessary.

We have added several lines of new data in the revised manuscript. We showed i) siRNA knockdown of TRPV6 resulted in a significant increase in LoVo cell proliferation (Figure 6A), and ii) expression of PP2A-Cα^L199P^ and PP2A-Cα^H118N^, two dominant-negative PP2A in LoVo cells significantly increased their proliferation (Figures 6C). Representative FCAS profiles are now included in Figure 5---figure supplement 1, 2, 4). The cell viability was assessed by MTT assays. There was no significant change in cell viability in GdCl~3~, BAPTA-AM, and Okadaic acid treated cells but Ruthenium red treatment resulted in a modest but statistically significant decrease in cell viability (Figure 6---figure supplement 2). These new and genetic data provide further support that the TRPV6-\[Ca^2+^\]~i~-PP2A signaling mechanism is functional in human epithelial carcinoma cells.
